Shanghai Fosun Pharmaceutical (Group) Co., Ltd. SFOSF
2.20 USD +0.03 (+1.15%)
At closeOct 30, 2026, 4:00 PM EDT
2.20 Day range 2.20
1.93 52-week range 3.30
- YTD
- -12.00%
- 1 year
- -33.33%
- Market cap
- 8.28B
- EPS (ttm)
- 0.19
- P/E ratio
- 11.58
- YTD return
- -12.00%
- 1-year return
- -33.33%
- Volume
- 100
- Avg volume
- 112
- Open
- 2.20
- Previous close
- 2.18
- Day's range
- 2.20 – 2.20
- 52-week range
- 1.93 – 3.30
- Earnings date
- Aug 26, 2026
2Y +0.34 (+18.58%)
Next earnings
Aug 26, 2026
Expected Aug 26, 2026. Consensus EPS estimate 0.04162.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Aug 26, 2026 | Dec 31, 2025 | 0.04162 | — | — | — |
| Apr 27, 2026 | Mar 31, 2026 | — | 0.04795 | — | — |
| Aug 26, 2025 | Jun 30, 2025 | — | 0.04907 | — | — |
| Apr 29, 2025 | Mar 31, 2025 | — | 0.03944 | — | — |
| Mar 25, 2025 | Dec 31, 2024 | — | 0.03904 | — | — |
News
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SFOSF) Q2 2026 Earnings Call Transcript 
Fosun Pharma Announces H-Share Repurchase Plan of Up to HK$ 1 Billion 
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (OTCMKTS:SFOSF) Short Interest Up 21.2% in January 
Generic drugmakers start shipping copies of Takeda's ADHD drug Vyvanse 
Fosun Pharma Shares Gain After Tie-Up With New Covid Drug Supplier Genuine Biotech 
Week In Review: Nuance In-Licenses RSV Vaccine In $225 Million Deal 
Pandemic Accelerates China's Drive Into mRNA Treatments 
Week In Review: Genscript And Its Legend Bio Subsidiary Raise $1 Billion From Hillhouse 
Week In Review: CANbridge Licenses LogicBio's Adeno-Associated Virus For Gene Therapies In $591 Million Deal
Your note
Sign in to keep a note on SFOSF — it syncs with the Stock Master app.